Comparative Pharmacology
Head-to-head clinical analysis: PROCAINAMIDE HYDROCHLORIDE versus QUALAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCAINAMIDE HYDROCHLORIDE versus QUALAQUIN.
PROCAINAMIDE HYDROCHLORIDE vs QUALAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractory period in atrial and ventricular myocardium.
Quinine is a cinchona alkaloid that acts as a blood schizonticide against Plasmodium species. It inhibits heme polymerase in the parasite, leading to accumulation of toxic heme and parasite death. It also has weak gametocytocidal activity against P. vivax and P. malariae.
Oral: 250-500 mg every 3-6 hours. IV: Loading dose 15-18 mg/kg infused over 25-30 minutes, then maintenance infusion 1-4 mg/min. Maximum total daily dose: 4 g.
325-650 mg orally every 6 hours as needed for pain; maximum 2.6 g/day.
None Documented
None Documented
Terminal elimination half-life: 2.5-5 hours (normal renal function); prolonged to 11-20 hours in renal impairment (e.g., CrCl <30 mL/min); clinical context: requires dosing adjustment in renal failure; NAPA half-life: 6-8 hours (normal), up to 40 hours in renal failure.
Terminal elimination half-life approximately 8 hours in healthy adults; prolonged in hepatic impairment (up to 12-18 hours) and severe malaria (up to 14-20 hours).
Renal: ~50-60% unchanged via glomerular filtration and tubular secretion; hepatic metabolism to N-acetylprocainamide (NAPA, active) accounts for ~15-30% of dose, further eliminated renally; biliary/fecal: negligible (<5%).
Renal (approximately 20% unchanged; remainder as metabolites); biliary/fecal (minor).
Category A/B
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)